The 11β-hydroxysteroid dehydrogenases: Functions and physiological effects

Molecular and Cellular Endocrinology

Volumn 151, Issue 1-2, 1999, Pages 121-127

  Krozowski, Zygmunt ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

11 hydroxysteroid dehydrogenase; Glucocorticoid; Hypertension; Mineralocorticoid; Receptor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; HYDROXYSTEROID DEHYDROGENASE; STEROID;

CLUSTER ANALYSIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ISOLATION; GENE DELETION; GENE MUTATION; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; HUMANS; HYDROXYSTEROID DEHYDROGENASES; STEROIDS;

EID: 0033602686     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00256-1     Document Type: Article

References (70)

1. Albiston A.L., Smith R.E., Krozowski Z.S. Sex- and tissue-specific regulation of 11β-hydroxysteroid dehydrogenase mRNA. Mol. Cell. Endocrinol. 109:1995;183-188.
2. Baker M.E., Grundy W.N., Elkan C.P. Spinach CSP41, an mRNA-binding protein and ribonuclease, is homologous to nucleotide-sugar epimerases and hydroxysteroid dehydrogenases. Biochem. Biophys. Res. Commun. 248:1998;250-254.
3. Brand E., Kato N., Chatelain N., Krozowski Z.S., Jeunemaitre X., Corvol P., Plouin P.F., Cambien F., Pascoe L., Soubrier F. Structural analysis and evaluation of the 11(-hydroxysteroid dehydrogenase type 2 (11b-HSD2) gene in human essential hypertension. J. Hyperten. 16:1998;1627-1633.
4. Brem A.S., Bina R.B., King T., Morris D.J. 11β OH-progesterone affects vascular glucocorticoid metabolism and contractile response. Hypertension. 30:1997;449-454.
5. Brem A.S., Bina R.B., King T.C., Morris D.J. Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension. 31:1998;459-462.
6. Brown R.W., Diaz R., Robson A.C., Kotelevtsev Y.V., Mullins J.J., Kaufman M.H., Seckl J.R. The ontogeny of 11β-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology. 137:1996;794-797.
7. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect 'Cushing's disease of the omentum?'. Lancet. 349:1997;1210-1213.
8. Dave-Sharma S., Wilson R.C., Harbison M.D., Newfield R., Azar M.R., Krozowski Z.S., Funder J.W., Shackleton C.H., Bradlow H.L., Wei J.Q., Hertecant J., Moran A., Neiberger R.E., Balfe J.W., Fattah A., Daneman D., Akkurt H.I., De Santis C., New M.I. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 83:1998;2244-2254.
9. Diaz R., Brown R.W., Seckl J.R. Distinct ontogeny of glucocorticoid and mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase types I and II mRNAs in the fetal rat brain suggest a complex control of glucocorticoid actions. J. Neurosci. 18:1998;2570-2580.
10. Dodic M., May C.N., Coghlan J.P. Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. Steroids. 63:1998;99-104.
11. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., deKloet E.R., Monder C. Localisation of 11β-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet. 2:1988;986-989.
12. Escher G., Nawrocki A., Staub T., Vishwanath B.S., Frey B.M., Reichen J., Frey F.J. Down-regulation of hepatic and renal 11β-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology. 114:1998;175-184.
13. Escher G., Vogt B., Beck T., Guntern D., Frey B.M., Frey F.J. Reduced 11β-hydroxysteroid dehydrogenase activity in the remaining kidney following nephrectomy. Endocrinology. 139:1998;1533-1539.
14. Fejes-Toth G., Pearce D., Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc. Natl. Acad. Sci. USA. 95:1998;2973-2978.
15. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor mediated. Science. 242:1988;583-585.
16. Funder J.W., Krozowski Z., Myles K., Sato A., Sheppard K.E., Young M. Mineralocorticoid receptors, salt and hypertension. Recent Prog. Horm. Res. 52:1997;247-260.
17. Gomez-Sanchez E.P., Gomez-Sanchez C.E. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am. J. Physiol. 263:1992;E1125-E1130.
18. Gomez-Sanchez E.P., Fort C., Thwaites D. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats. Am. J. Physiol. 262:1992;E96-99.
19. Hirasawa G., Sasano H., Takahashi K., Fukushima K., Suzuki T., Hiwatashi N., Toyota T., Krozowski Z.S., Nagura H. Colocalization of 11β-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J. Clin. Endocrinol. Metab. 82:1997;3859-3863.
20. Hundertmark S., Buhler H., Rudolf M., Weitzel H.K., Ragosch V. Inhibition of 11β-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. J. Endocrinol. 155:1997;171-180.
21. Kelly J.J, Tam S.H., Williamson P.M., Lawson J., Whitworth J.A. The nitric oxide system and cortisol-induced hypertension in humans. Clin. Exp. Pharm. Physiol. 25:1998;945-946.
22. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R.W., Seckl J.R., Mullins J.J. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA. 94:1997;14924-14929.
23. Krozowski Z.S., Rundle S.E., Wallace C., Castell M.J., Shen J.H., Dowling J., Funder J.W., Smith A.I. Immunolocalization of renal mineralocorticoid receptors with an antiserum against a peptide deduced from the complementary deoxyribonucleic acid sequence. Endocrinology. 125:1989;192-198.
24. Krozowski Z., Stuchbery S., White P., Monder C., Funder J.W. Characterization of 11β-hydroxysteroid dehydrogenase gene expression: identification of multiple unique forms of messenger ribonucleic acid in the rat kidney. Endocrinology. 127:1990;3009-3013.
25. Krozowski Z., Maguire J.A., Stein-Oakley A.N., Dowling J., Smith R.E., Andrews R.K. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J. Clin. Endocrinol. Metab. 80:1995;2203-2209.
26. Kyossev Z., Walker P.D., Reeves W.B. Immunolocalization of NAD-dependent 11β-hydroxysteroid dehydrogenase in human kidney and colon. Kidney Int. 49:1996;271-281.
27. Li A., Tedde R., Krozowski Z.S., Pala A., Li K.X., Shackleton C.H., Mantero F., Palermo M., Stewart P.M. Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess. Am. J. Hum. Genet. 63:1998;370-379.
28. Lo Y.H., Sheff M.F., Latif S.A., Ribeiro C., Silver H., Brem A.S., Morris D.J. Kidney 11β-HSD2 is inhibited by glycyrrhetinic acid-like factors in human urine. Hypertension. 29:1997;500-505.
29. Lombes M., Alfaidy N., Eugene E., Lessana A., Farman N., Bonvalet J.P. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation. 92:1995;175-182.
30. Low S.C., Chapman K.E., Edwards C., Wells T., Robinson I., Seckl J.R. Sexual dimorphism of hepatic 11β-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J. Endocrinol. 143:1994;541-548.
31. Morris D.J., Latif S.A., Rokaw M.D., Watlington C.O., Johnson J.P. A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am. J. Physiol. 274:1998;C1245-1252.
32. + on glycyrrhetinic acid-like factors (kidney 11β-(HSD2)-GALFs) in human essential hypertension. Hypertension. 31:1998;469-472.
33. Mune T., White P.C. Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension. 27:1996;1193-1199.
34. Murotsuki J., Gagnon R., Pu X., Yang K. Chronic hypoxemia selectively down-regulates 11β-hydroxysteroid dehydrogenase type 2 gene expression in the fetal sheep kidney. Biol. Reprod. 58:1998;234-239.
35. Napolitano A., Voice M.W., Edwards C.R., Seckl J.R., Chapman K.E. 11β-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J. Steroid Biochem. Mol. Biol. 64:1998;251-260.
36. NarayFejesToth A., FejesToth G. Subcellular localization of the type 2 11β-hydroxysteroid dehydrogenase - a green fluorescent protein study. J. Biol. Chem. 271:1996;15436-15442.
37. Naray-Fejes-Toth A., Fejes-Toth G. Extranuclear localization of endogenous 11β-hydroxysteroid dehydrogenase-2 in aldosterone target cells. Endocrinology. 139:1998;2955-2959.
38. Naray-Fejes-Toth A., Rusvai E., Fejes-Toth G. Mineralocorticoid receptors and 11β-steroid dehydrogenase activity in renal principal and intercalated cells. Am. J. Physiol. 266:1994;F76-F80.
39. Nikkila H., Tannin G.M., New M.I., Taylor N.F., Kalaitzoglou G., Monder C., White P.C. Defects in the HSD11 gene encoding 11β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J. Clin. Endocrinol. Metab. 77:1993;687-691.
40. Nokelainen P., Peltoketo H., Vihko R., Vihko P. Expression cloning of a novel estrogenic mouse 17β-hydroxysteroid dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described as a prolactin receptor-associated protein (PRAP) in rat. Mol. Endocrinol. 12:1998;1048-1059.
41. Nyirenda M.J., Lindsay R.S., Kenyon C.J., Burchell A., Seckl J.R. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J. Clin. Invest. 101:1998;2174-2181.
42. Obeyesekere V.R., Trzeciak W.H., Li K.X.Z., Krozowski Z.S. Serines at the active site of 11β-hydroxysteroid dehydrogenase type I determine the rate of catalysis. Biochem. Biophys. Res. Commun. 250:1998;469-473.
43. Obeyesekere V.R., Li K.X.Z., Ferrari P., Krozowski Z. Truncation of the N- and C-terminal regions of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. Mol. Cell. Endocrinol. 131:1997;173-182.
44. Oppermann U., Netter K.J., Maser E. Cloning and primary structure of murine β-hydroxysteroid dehydrogenase microsomal carbonyl reductase. Eur. J. Biochem. 227:1995;202-208.
45. Puranen T., Poutanen M., Ghosh D., Vihko P., Vihko R. Characterization of structural and functional properties of human 17β-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. Mol. Endocrinol. 11:1997;77-86.
46. Ricketts M.L., Shoesmith K.J., Hewison M., Strain A., Eggo M.C., Stewart P.M. Regulation of 11β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J. Endocrinol. 156:1998;159-168.
47. Ricketts M.L., Verhaeg J.M., Bujalska I., Howie A.J., Rainey W.E., Stewart P.M. Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J. Clin. Endocrinol. Metab. 83:1998;1325-1335.
48. Robson A.C., Leckie C.M., Seckl J.R., Holmes M.C. 11β-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain Res. Mol. Brain Res. 61:1998;1-10.
49. Roland B.L., Li K., Funder J.W. Hybridization histochemical localization of 11β-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology. 136:1995;4697-4700.
50. Sasano H., Frost A.R., Saitoh R., Matsunaga G., Nagura H., Krozowski Z.S., Silverberg S.G. Localization of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II in human breast and its disorders. Anticancer Res. 17:1997;2001-2007.
51. Shams M., Kilby M.D., Somerset D.A., Howie A.J., Gupta A., Wood P.J., Afnan M., Stewart P.M. 11β-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum. Reprod. 13:1998;799-804.
52. Shimojo M., Ricketts M.L., Petrelli M.D., Moradi P., Johnson G.D., Bradwell A.R., Hewison M., Howie A.J., Stewart P.M. Immunodetection of 11β-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology. 138:1997;1305-1311.
53. Simon A., Hellman U., Wernstedt C., Eriksson U. The retinal pigment epithelial-specific 11-cis retinol dehydrogenase belongs to the family of short chain alcohol dehydrogenases. J. Biol. Chem. 270:1995;1107-1112.
54. Slight S., Ganjam V.K., Nonneman D.J., Weber K.T. Glucocorticoid metabolism in the cardiac interstitium: 11β-hydroxysteroid dehydrogenase activity in cardiac fibroblasts. J. Lab. Clin. Med. 122:1993;180-187.
55. Slight S.H., Ganjam V.K., GomezSanchez C.E., Zhou M.Y., Weber K.T. High affinity NAD(+)-dependent 11β-hydroxysteroid dehydrogenase in the human heart. J. Mol. Cell. Cardiol. 28:1996;781-787.
56. Smith R.E., Krozowski Z.S. 11β-hydroxysteroid dehydrogenase type I enzyme in the hearts of normotensive and spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 23:1996;642-647.
57. Smith R.E., Li K.X.Z., Andrews R.K., Krozowski Z. Immunohistochemical and molecular characterization of the rat 11β-hydroxysteroid dehydrogenase type II enzyme. Endocrinology. 138:1997;540-547.
58. Smith R.E., Salamonsen L.A., Komesaroff P.A., Li K.X., Myles K.M., Lawrence M., Krozowski Z. 11β-hydroxysteroid dehydrogenase type II in the human endometrium: localization and activity during the menstrual cycle. J. Clin. Endocrinol. Metab. 82:1997;4252-4257.
59. Smolenicka Z., Bach E., Schaer A., Liechti-Gallati S., Frey B.M., Frey F.J., Ferrari P. A new polymorphic restriction site in the human 11β-hydroxysteroid dehydrogenase type 2 gene. J. Clin. Endocrinol. Metab. 83:1998;1814-1817.
60. Song W., Chen J., Dean W.L., Redinger R.N., Prough R.A. Purification and characterization of hamster liver microsomal 7α-hydroxycholesterol dehydrogenase similarity to type i 11β-hydroxysteroid dehydrogenase. J. Biol. Chem. 273:1998;16223-16228.
61. Soro A., Ingram M.C., Tonolo G., Glorioso N., Fraser R. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension. 25:1995;67-70.
62. Souness G.W., Morris D.J. The mineralocorticoid-like actions conferred on corticosterone by carbenoxolone are inhibited by the mineralocorticoid receptor (type-I) antagonist RU28318. Endocrinology. 129:1991;2451-2456.
63. Stewart, P.M., Krozowski, Z.S., 1999. 11β-hydroxysteroid dehydrogenase. Vit. Horm. (in press).
64. van Steensel B., van Binnendijk E.P., Hornsby C.D., van der Voort H.T., Krozowski Z.S., de Kloet E.R., van Driel R. Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. J. Cell Sci. 109:1996;787-792.
65. Voice M.W., Seckl J.R., Edwards C.R.W., Chapman K.E. 11β-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem. J. 317:1996;621-625.
66. Walker B.R., Yau J.L., Brett L.P., Seckl J.R., Monder C., Williams B.C., Edwards C.R. 11β-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology. 129:1991;3305-3312.
67. Walker B.R., Williamson P.M., Brown M.A., Honour J.W., Edwards C.R., Whitworth J.A. 11β-hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy. Hypertension. 25:1995;626-630.
68. Watson B., Bergman S.M., Myracle A., Callen D.F., Acton R.T., Warnock D.G. Genetic association of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension. 28:1996;478-482.
69. White P.C., Mune T., Agarwal A.K. 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 18:1997;135-156.
70. Wilson R.C., Dave-Sharma S., Wei J.Q., Obeyesekere V.R., Li K., Ferrari P., Krozowski Z.S., Shackleton C.H., Bradlow L., Wiens T., New M.I. A genetic defect resulting in mild low-renin hypertension. Proc. Natl. Acad. Sci. USA. 95:1998;10200-10225.